


# Netupitant-Palonosetron FDC Market Statistics 2021: Rising Investment Opportunities for Major Players

PORTLAND, OR, UNITED STATES, October 21, 2021 /EINPresswire.com/ -- Netupitant-palonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years. High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future.



“

Netupitant-Palonosetron FDC market holds a substantial scope for growth globally. The market, which is in its growth stage, however, is anticipated to contribute significantly”  
*Allied Market Research*

Explore Report Description@

<https://www.alliedmarketresearch.com/netupitant-palonosetron-FDC-market>

The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-induced nausea and vomiting

(CINV). Moreover, palonosetron helps in the blockage of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors and reduces CINV.

Presently, patient pool segment has witnessed large-scale adoption of netupitant-palonosetron FDC drugs due to rise in number of patient undergoing chemotherapy. Moreover, increase in introduction of novel delivery methods to improve patient compliance and the efficacy of

combination therapy is accepted to improve by patient pool. Rise in number of patient undergoing chemotherapy and need for higher efficiency drugs for the treatment of cancer patients are expected to drive the growth of the market. However, the current antiemetic efficacy is about 70%-80% in patients treated with highly emetogenic cytotoxic drugs. One of the potential factors that explains this suboptimal response is variability in genes encoding enzymes and proteins, which play a role in metabolism, transport, and receptors related to antiemetic drugs.

The significant impacting factors include growth in number of patients who undergo chemotherapy and introduction of novel drug delivery methods to improve patient compliance, and improvements in control of nausea and vomiting due to chemotherapy. Along with these factors, the market is influenced by the advancements in technology to discover new high-potential FDC drugs that enhance R&D efforts to discover antiemetic therapy. The abovementioned factors collectively create opportunities for the market growth, while factor such as high price of CINV drugs restrain the growth of the market. However, each factor is expected to have its definite impact on the market during the forecast period.

For Purchase Enquiry at: <https://www.alliedmarketresearch.com/purchase-enquiry/1831>

Geographically, North America was the dominant regional market for netupitant–palonosetron FDC drugs, in terms of revenue, due to growth in incidence of CINV among patients. These drugs are expected to have significant impact on the revenue of the overall market. Approval of new drugs such as rolapitant and Sustol (APF-530) is expected to boost the growth of the CINV drugs in the US market during the forecast period. Europe was the second largest regional market for netupitant–palonosetron FDC drugs, in terms of revenue, due to growth in demand for netupitant–palonosetron FDC drugs among patients.

Acacia Pharma, Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd. are some of the major players discussed in the report.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: <https://www.alliedmarketresearch.com/avenue/trial/starter>

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

Trending Reports in Healthcare Industry:  
[Ablation Technologies Market Global Research By 2030](#)

[Hearing Aids Market Global Research By 2030](#)

[Prostate Cancer Market Global Research By 2030](#)

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts

David Correa  
Allied Analytics LLP  
8007925285 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/554437618>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.